<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="pone.0163159.t002" orientation="portrait" position="float">
 <object-id pub-id-type="doi">10.1371/journal.pone.0163159.t002</object-id>
 <label>Table 2</label>
 <caption>
  <title>Hypotheses and projections for the main model scenarios (see also 
   <xref ref-type="fig" rid="pone.0163159.g005">Fig 5</xref>).
  </title>
 </caption>
 <alternatives>
  <graphic id="pone.0163159.t002g" xlink:href="pone.0163159.t002" xmlns:xlink="http://www.w3.org/1999/xlink"/>
  <table frame="hsides" rules="groups">
   <colgroup span="1">
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
   </colgroup>
   <thead>
    <tr>
     <th align="left" rowspan="1" colspan="1">Hypotheses</th>
     <th align="left" rowspan="1" colspan="1">Concentrated HIV epidemics</th>
     <th align="left" rowspan="1" colspan="1">Generalised HIV epidemics</th>
     <th align="left" rowspan="1" colspan="1">Hyperendemic HIV epidemics</th>
    </tr>
   </thead>
   <tbody>
    <tr>
     <td align="left" style="background-color:#c1c1c1" rowspan="1" colspan="1"> HIV prevalence (h)</td>
     <td align="left" style="background-color:#c1c1c1" rowspan="1" colspan="1">≈ 1%</td>
     <td align="left" style="background-color:#c1c1c1" rowspan="1" colspan="1">≈ 10%</td>
     <td align="left" style="background-color:#c1c1c1" rowspan="1" colspan="1">≈ 35%</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1"> Intra-couple ART prevention effectiveness (r)</td>
     <td align="left" rowspan="1" colspan="1">Available evidence suggests that ART confers a similar prevention benefit to MSM as to heterosexual serodiscordant couples</td>
     <td align="left" rowspan="1" colspan="1">A systematic review and meta-analysis of prospective studies among serodiscordant couples suggests that ART may reduce HIV incidence by 66% to 96%</td>
     <td align="left" rowspan="1" colspan="1">A systematic review and meta-analysis of prospective studies among serodiscordant couples suggests that ART may reduce HIV incidence by 66% to 96%</td>
    </tr>
    <tr>
     <td align="left" style="background-color:#c1c1c1" rowspan="1" colspan="1"> Fraction of PLWH who know HIV status (d)</td>
     <td align="left" style="background-color:#c1c1c1" rowspan="1" colspan="1">In some concentrated HIV epidemics (e.g. MSM in Switzerland), more than 75% of PLWH know their status, but in other key populations (e.g. people who inject drugs) in Asia, this fraction may be far below 50%</td>
     <td align="left" style="background-color:#c1c1c1" rowspan="1" colspan="1">About half of all PLWH in Sub-Saharan Africa know their status, but knowledge of HIV status is lower among youth and men.</td>
     <td align="left" style="background-color:#c1c1c1" rowspan="1" colspan="1">About half of all PLWH in Sub-Saharan Africa know their status, but knowledge of HIV status is lower among youth and men.</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1"> Fraction of ART patients among 
      <italic>diagnosed</italic> PLWH (a)
     </td>
     <td align="left" rowspan="1" colspan="1">Estimates range from 40% in the USA to 77% in Australia</td>
     <td align="left" rowspan="1" colspan="1">Close to 90% of PLWH who know their status in sub-Saharan Africa are receiving ART.</td>
     <td align="left" rowspan="1" colspan="1">Close to 90% of PLWH who know their status in sub-Saharan Africa are receiving ART.</td>
    </tr>
    <tr>
     <td align="left" style="background-color:#c1c1c1" rowspan="1" colspan="1"> Level of HIV serosorting (n)</td>
     <td align="left" style="background-color:#c1c1c1" rowspan="1" colspan="1">Estimates for the prevalence of serosorting among MSM range between 10% and 40%</td>
     <td align="left" style="background-color:#c1c1c1" rowspan="1" colspan="1">There are currently no quantitative data on the extent of serosorting in generalized epidemics</td>
     <td align="left" style="background-color:#c1c1c1" rowspan="1" colspan="1">There are currently no quantitative data on the extent of serosorting in hyperendemic epidemics</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">
      <bold>Projections</bold>
     </td>
     <td align="left" rowspan="1" colspan="1"/>
     <td align="left" rowspan="1" colspan="1"/>
     <td align="left" rowspan="1" colspan="1"/>
    </tr>
    <tr>
     <td align="left" style="background-color:#c1c1c1" rowspan="1" colspan="1"> Effect of ART clusters</td>
     <td align="left" style="background-color:#c1c1c1" rowspan="1" colspan="1">ART clusters may enhance impact of ART on HIV incidence by up to 50% if intra-couple ART prevention effectiveness is poor</td>
     <td align="left" style="background-color:#c1c1c1" rowspan="1" colspan="1">ART clusters may enhance impact of ART on HIV incidence by up to 50% if intra-couple ART prevention effectiveness is poor</td>
     <td align="left" style="background-color:#c1c1c1" rowspan="1" colspan="1">ART clusters may reduce ART impact by about 25% if intra-couple ART prevention effectiveness is high</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1"> Effect of HIV serosorting</td>
     <td align="left" rowspan="1" colspan="1">HIV serosorting reduces the impact of ART on HIV incidence, but does not influence the relative effect of ART clusters</td>
     <td align="left" rowspan="1" colspan="1">HIV serosorting reduces the impact of ART on HIV incidence, but does not influence the relative effect of ART clusters</td>
     <td align="left" rowspan="1" colspan="1">HIV serosorting reduces the impact of ART on HIV incidence, but does not influence the relative effect of ART clusters</td>
    </tr>
   </tbody>
  </table>
 </alternatives>
</table-wrap>
